• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Editorial Staff
    • Publication Ethics
    • Indexing and Abstracting
    • Related Links
    • FAQ
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter Telegram
Asian Pacific Journal of Cancer Prevention
Articles in Press
Current Issue
Journal Archive
Volume Volume 19 (2018)
Volume Volume 18 (2017)
Issue Issue 12
Issue Issue 11
Issue Issue 10
Issue Issue 9
Issue Issue 8
Issue Issue 7
Issue Issue 6
Issue Issue 5
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 17 (2016)
Volume Volume 16 (2015)
Volume Volume 15 (2014)
Volume Volume 14 (2013)
Volume Volume 13 (2012)
Volume Volume 12 (2011)
Volume Volume 11 (2010)
Volume Volume 10 (2009)
Volume Volume 9 (2008)
Volume Volume 8 (2007)
Volume Volume 7 (2006)
Volume Volume 6 (2005)
Volume Volume 5 (2004)
Volume Volume 4 (2003)
Volume Volume 3 (2002)
Volume Volume 2 (2001)
Volume Volume 1 (2000)
Taghiloo, S., Allahmoradi, E., Ebadi, R., Tehrani, M., Hosseini-Khah, Z., Janbabai, G., Shekarriz, R., Asgarian-Omran, H. (2017). Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia. Asian Pacific Journal of Cancer Prevention, 18(8), 2269-2274. doi: 10.22034/APJCP.2017.18.8.2269
Saeid Taghiloo; Esmaeil Allahmoradi; Reza Ebadi; Mohsen Tehrani; Zahra Hosseini-Khah; Ghasem Janbabai; Ramin Shekarriz; Hossein Asgarian-Omran. "Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia". Asian Pacific Journal of Cancer Prevention, 18, 8, 2017, 2269-2274. doi: 10.22034/APJCP.2017.18.8.2269
Taghiloo, S., Allahmoradi, E., Ebadi, R., Tehrani, M., Hosseini-Khah, Z., Janbabai, G., Shekarriz, R., Asgarian-Omran, H. (2017). 'Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia', Asian Pacific Journal of Cancer Prevention, 18(8), pp. 2269-2274. doi: 10.22034/APJCP.2017.18.8.2269
Taghiloo, S., Allahmoradi, E., Ebadi, R., Tehrani, M., Hosseini-Khah, Z., Janbabai, G., Shekarriz, R., Asgarian-Omran, H. Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia. Asian Pacific Journal of Cancer Prevention, 2017; 18(8): 2269-2274. doi: 10.22034/APJCP.2017.18.8.2269

Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia

Article 38, Volume 18, Issue 8, August 2017, Page 2269-2274  XML PDF (576 K)
Document Type: Research Articles
DOI: 10.22034/APJCP.2017.18.8.2269
Authors
Saeid Taghiloo1; Esmaeil Allahmoradi1; Reza Ebadi1; Mohsen Tehrani1, 2; Zahra Hosseini-Khah3; Ghasem Janbabai4; Ramin Shekarriz4; Hossein Asgarian-Omran 1, 5
1Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
2Molecular and Cell-Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
3Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
4Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
5Immunogenetics Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Receive Date: 11 June 2017,  Revise Date: 19 July 2017,  Accept Date: 01 August 2017 
Abstract
 
Background: Deviation of host immune response by engagement of inhibitory receptors is one of the well-known mechanisms of tumor cells for immune evasion and survival. PD-1/PD-L1 and Tim-3/Gal-9 axes are two major pathways in this area which their contribution has been documented in a variety of malignancies. In this study, Gal-9 and PD-L1 expression was investigated in leukemic cells from patients with Chronic Lymphocytic Leukemia (CLL). Methods: Peripheral blood mononuclear cells (PBMCs) were obtained from 25 untreated CLL patients and 15 sex- and age-matched healthy controls. CLL patients were classified into different clinical stages based on the Rai staging system. Total RNA was extracted from all samples and applied for cDNA synthesis. Relative expression of Gal-9 and PD-L1 mRNA was determined by Real-Time PCR using β-actin as a housekeeping gene. Results: Gal-9 and PD-L1 mRNA was significantly more expressed in CLL patients compared to healthy controls (ppatients in advanced clinical stages showed higher expression of Gal-9 and PD-L1 in comparison to patients in early clinical stages (pConclusion: Our promising results regarding over-expression of Gal-9 and PD-L1 in CLL patients call future complementary studies to more evaluate and confirm these pathways for immunotherapy approaches of this malignancy. Upregulation of both Gal-9 and PD-L1 in CLL patients with advanced clinical stages introduces them as useful prognostic biomarkers for disease progression.
Keywords
Exhausted T cell; Galectin-9; PD-L1; Chronic Lymphocytic Leukemia
Main Subjects
Hematologic Oncology
Statistics
Article View: 402
PDF Download: 282
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

 



 

Journal Management System. Designed by sinaweb.